A Brief Review on Gastro Retentive System

 

Dahake MN, Wattamwar PP, Bongirwar RA, Mohale DS, Bakal RL and Chandewar AV

P.Wadhwani College of Pharmacy, Yavatmal (M.S.) India

 

ABSTRACT:

Oral delivery of drug is the most preferable route of drug delivery due to ease of administration, patient compliance and flexibility in formulation etc. However, it is a well accepted fact that it is difficult to predict the real in vivo time of release with solid, oral controlled release dosage forms. Various attempts have been made to prolong the retention time of the dosage form in the stomach. One such approach is development of floating Microspheres involves preparation of a device that remains buoyant in the stomach contents due to its lower density than that of the gastric fluids.Floating microspheres are gastro-retentive drug delivery systems based on non-effervescent approach. These microspheres are characteristically free flowing powders consisting of proteins or synthetic polymers, ideally having a size less than 200 micrometer. Floating microspheres are prepared by solvent diffusion and evaporation methods to create the hollow inner core. Floating microspheres are specially gaining attention due to their wide applicability in the targeting of drugs to stomach.

 

KEYWORDS: Oral controlled release dosage form, retention time, floating microsphere.

 

INTRODUCTION:

Oral delivery of drug is the most preferable route of drug delivery due to ease of administration, patient compliance and flexibility in formulation etc. However, it is a well accepted fact that it is difficult to predict the real in vivo time of release with solid, oral controlled release dosage forms. Various attempts have been made to prolong the retention time of the dosage form in the stomach. One such method is the preparation of a device that remains buoyant in the stomach contents due to its lower density than that of the gastric fluids.

 

The uniform distribution of these multiple unit dosage forms along the GIT could result in more reproducible drug absorption and reduced risk of local irritation; this gave birth to oral controlled drug delivery and led to development of Gastro-retentive floating microspheres1,2.

 

Floating drug delivery systems (FDDSs) are expected to remain buoyant in a lasting way upon the gastric contents and consequently to enhance the bioavailability of drugs. The various buoyant preparations include hollow microspheres, granules, powders, tablets, capsules, pills and laminated films. Floating microspheres are specially gaining attention due to their wide applicability in the targeting of drugs to stomach. These floating microspheres have the advantage that they remain buoyant and distributed uniformly over the gastric fluid to avoid the vagaries of gastric emptying and release the drug for prolonged period of time. The need for gastro retentive dosage forms (GRDFs) has led to extensive efforts in both academia and industry towards the development of such drug delivery systems. These efforts resulted in GRDFs that were designed, in large part, based on the following approaches:

(a) Low density form of the DF that causes buoyancy in gastric fluid3

(b) High density DF that is retained in the bottom of the stomach4

(c) Bioadhesion to stomach mucosa5

 


(d) Slowed motility of the gastrointestinal tract by concomitant administration of drugs or pharmaceutical excipients6

(e) Expansion by swelling or unfolding to a large size which limits emptying of the DF through the pyloric sphincter.7

Various attempts have been done to retain the dosage form in the stomach as a way of increasing retention time:

 

1. Bio/Mucoadhesive Systems:

The term bioadhesion describe materials that bind to the biological substrates, such as mucosal memberes. Adhesion of bioadhesive drug delivery devices to the mucosal tissue offeres the possibility of creating an intimate and prolonged contact at the site of administration. This prolonged residence time can result in the enhanced absorption and in combination with a controlled release of drug also improved patient compliance by reducing the frequency of administration.  The epithelial adhesive properties of mucin have been applied in the development of gastro retentive drug delivery systems 8, 9.

 

2. Floating Systems:

Floating systems are low-density systems that have sufficient buoyancy to float over the gastric contents and remain in the stomach for a prolonged period. While the system floats over the gastric contents, the drug is released slowly at the desired rate, which results in increased gastro-retention time and reduces fluctuation in plasma drug concentration10,11,12.

 

3. Swelling Systems:

These are capable of swelling to a size that prevents their passage through the pylorus; as a result, the dosage form is retained in the stomach for a longer period of time. Upon coming in contact with gastric fluid, the polymer imbibes water and swells.­13,14

 

TYPES OF FLOATING DRUG DELIVERY SYSTEM:

Floating systems are classified as follows:

1. Effervescent Systems

2. Non-Effervescent Systems

 

1. Effervescent Systems:

A. Volatile liquid containing systems:

The Gastric retention times of a drug delivery system can be sustained by incorporating an inflatable chamber, which contains a liquid e.g. ether, cyclopentane, that gasifies at body temperature to cause the inflatation of the chamber in the stomach. The device may also consist of a bioerodible plug made up of PVA, Polyethylene, etc. that gradually dissolves causing the inflatable chamber to release gas and collapse after a predetermined time to permit the spontaneous ejection of the inflatable systems from the stomach15.

 

B. Gas-generating Systems:

These buoyant delivery systems utilize effervescent reactions between carbonate/bicarbonate salts and citric/tartaric acid to liberate CO2, which gets entrapped in the gellified hydrocolloid layer of the systems thus decreasing its specific gravity and making it to float over chime.16

 

These buoyant systems utilize matrices prepared with swellable polymers like methocel, polysaccharides like chitosan, effervescent components like sodium bicarbonate, citric acid and tartaric acid or chambers containing a liquid that gasifies at body temperature. The optimal stoichiometric ratio of citric acid and sodium bicarbonate for gas generation is reported to be 0.76:1. The common approach for preparing these systems involves resin beads loaded with bicarbonate and coated with ethyl cellulose. The coating, which is insoluble but permeable, allows permeation of water. Thus, carbon dioxide is released, causing the beads to float in the stomach .Other approaches and materials that have been reported are highly swellable hydrocolloids and light mineral oils, a mixture of sodium alginate and sodium bicarbonate, multiple unit floating pills that generate carbon dioxide when ingested, floating minicapsules with a core of sodium bicarbonate, lactose and polyvinyl pyrrolidone coated with hydroxypropyl methylcellulose (HPMC), and floating systems based on ion exchange resin technology, etc.

 

2. Non-Effervescent Systems:

This type of system, after swallowing, swells unrestrained via imbibition of gastric fluid to an extent that it prevents their exit from the stomach. These systems may be referred to as the ‘plug-type systems’ since they have a tendency to remain lodged near the pyloric sphincter. One of the formulation methods of such dosage forms involves the mixing of drug with a gel, which swells in contact with gastric fluid after oral administration and maintains a relative integrity of shape and a bulk density of less than one within the outer gelatinous barrier. The air trapped by the swollen polymer confers buoyancy to these dosage forms.

 
a. Colloidalgel barrier systems:

Hydrodymamically balance system (HBS) was first design by Sheth and Tossounian in 1975. Such systems contains drug with gel forming hydrocolloids meant to remain buoyant on stomach contents. This system incorporate a high level of one or more gel forming highly swellable cellulose type hydrocolloids e.g. HEC, HPMC, NaCMC, Polysacchacarides and matrix forming polymers such as polycarbophil, polyacrylates and polystyrene, incorporated either in tablets or in capsules. On coming in contact with gastric fluid, the hydrocolloid in the system hydrates and forms a colloidal gel barrier around the gel surface. The air trapped by the swollen polymer maintains a density less than unity and confers buoyancy to this dosage forms14.

 

b. Microporous Compartment System:

This technology is based on the encapsulation of drug reservoir inside a microporous compartment with aperture along its top and bottom wall.16 The peripheral walls of the drug reservoir compartment are completely sealed to prevent any direct contact of the gastric mucosal surface with the undissolved drug. In stomach the floatation chamber containing entrapped air causes the delivery system to float over the gastric contents. Gastric fluid enters through the apertures, dissolves the drug, and carries the dissolve drug for continuous transport across the intestine for absorption.

 

c. Alginate beads:

Multiple unit floating dosage forms have been developed from freeze-dried calcium alginate.15 Spherical beads of approximately 2.5 mm in diameter can be prepared by dropping a sodium alginate solution in to aqueous solutions of calcium chloride, causing precipitation of calcium alginate. The beads are then separated snap and frozen in liquid nitrogen, and freeze dried at -40° for 24 h, leading to the formation of porous system, which can maintain a floating force over 12 hour.

 

d. Hollow microspheres:

Hollow microspheres (microballons), loaded with ibuprofen in their outer polymer shells were prepared by a novel emulsion-solvent diffusion method. The ehanol: dichloromethane solution of the drug and an enteric acrylic polymer was poured in to an agitated aqueous solution of PVA that was thermally controlled at 40°.The gas phase generated in dispersed polymer droplet by evaporation of dichloromethane formed in internal cavity in microspheres of the polymer with drug. The microballons floated continuously over the surface of acidic dissolution media containing surfactant for greater than 12 hour in vitro.

 

Development of floating microsphere:

Floating microspheres are gastro-retentive drug delivery systems based on non-effervescent approach. Hollow microspheres are in strict sense, spherical empty particles without core. These microspheres are characteristically free flowing powders consisting of proteins or synthetic polymers, ideally having a size less than 200 micrometer. As the system floats over gastric contents, the drug is released slowly at desired rate resulting in increased gastric retention. Solid biodegradable microspheres incorporating a drug dispersed or dissolved throughout particle matrix have the potential for controlled release of drugs 17,18

 

Diagram; floating microsphere in GI tract

 

Mechanism of Floating Microspheres:

When microspheres come in contact with gastric fluid the gel formers, polysaccharides and polymers hydrate to form a colloidal gel barrier that controls drug release.

 

As the exterior surface of the dosage form dissolves, the gel layer is maintained by the hydration of the adjacent hydrocolloid layer. The air trapped by the swollen polymer lowers the density and confers buoyancy to the microspheres. However a minimal gastric content needed to allow proper achievement of buoyancy18, 10, 11, 19.

 

Methods of Preparation:

1.        Single emulsion technique: - The natural polymers are dissolved or dispersed in the aqueous medium followed by dispersion in non-aqueous medium e.g. oil.

 

In the second step cross linking of dispersed globule is carried out. Cross linking can be achieved by means of heat or by using the chemical cross linkers. Cross linking by heat is affected by adding the dispersion to previously heated oil. Heat denaturation is however, not suitable for thermo labile drugs.

 

2.        Double emulsion technique: - Preparation involves formation of multiple emulsions of type w/o/w and is best suited to water soluble drugs, peptides, proteins and vaccines. This method can be use with both the natural as well as synthetic polymers.

 

3.        Polymerization technique:- Polymerization techniques are classified as,

a.        Normal polymerization

b.       Interfacial polymerization

 

4.        Phase separation cocervation technique: - In this technique polymer is first dissolved in the suitable solvent and the drug is dispersed by making its aqueous solution, if hydrophilic or dissolved in a polymer solution itself, if hydrophilic. Phase separation is then accomplished by changing the solution conditions by using any of the method mentioned above.

 

5.        Spray drying and spray congealing: - These methods are based on the drying of mist of polymer and drug in the air. Depending upon the removal of the solvent or cooling of the solution, the 2 processes are named spray drying and spray congealing respectively. The polymer is first dissolved in suitable volatile organic solvent such as dichloromethane, acetone, etc. The drug is then dispersed in the in the polymer solution under high speed homogenization. This dispersion is then atomized in stream of hot air. Atomization causes formation of small droplets from which solvent evaporates leading the formation of microsphere.

 

6.        Solvent extraction:- This method is used for preparation of micro particles, involves removal of organic phase by extraction of organic solvent. This method involves water miscible solvent such as isopropanol. And the organic phase is finally removed by extraction with water.17

 

Advantages:

1. Improves patient compliance by decreasing dosing frequency.

2. Better therapeutic effect of short half-life drugs can be achieved.

3. Gastric retention time is increased

4. Drug releases in controlled manner for prolonged period.

5. Site-specific drug delivery to stomach can be achieved.

6. Avoidance of gastric irritation, because of sustained release effect, floatability and uniform release of drug through multi particulate system.

7. Enhanced bioavailability

Ex. The bioavailability of riboflavin Controlled release (CR) gastro retentive drug formulation (GRDF) is significantly enhanced in comparison to the administration of non-GRDF CR polymeric formulations. There are several different processes, related to absorption and transit of the drug in the gastrointestinal tract, that act concomitantly to influence the magnitude of drug absorption.20

 

Applications:

1. FDDS can improve the pharmacotherapy of oral formulations and provide high and sustained drug concentrations along the gastric mucosa.

2. A floating dosage form is a feasible approach especially for drugs which have absorption sites in the upper small intestine.

3. The concept of FDDS has also been utilized in the development of various anti-reflux formulations.

4. Hollow microspheres can greatly improve the pharmacotherapy of the stomach through local drug release, leading to high drug concentrations at the gastric mucosa, thus eradicating Helicobacter pylori from the sub-mucosal tissue of the stomach and making it possible to treat stomach and duodenal ulcers, gastritis and oesophagitis.

 

Limitations:

1) Requirement of high level of fluid in the stomach for the delivery system to float and work efficiently.

2) These systems also require the presence of food to delay their gastric emptying.

 

CONCLUSION:

Floating microspheres enable prolonged and continuous input of drugs to the upper part of GI tract and improves the bioavailability of the medications that are characterized by narrow absorption window. Ultimately floating microsphere provides a means to utilize all pharmacokinetic and pharmacodynamics advantages of controlled release dosage forms for such drugs. From the observations it may be concluded that drug absorption in the gastrointestinal tract is a highly variable process and prolonging gastric retention of the dosage form extends the time for drug absorption. Thus, gastro retentive dosage form provides an additional advantage for a drug that are primarily absorbed in the upper segment of GI tract. Although there are number of difficulties to be worked out to achieve prolonged gastric retention a large number of companies are focusing towards commercializing this technique.

 

REFERENCES:

1.        Jain, N.K., “Controlled Novel Drug Delivery”, Ist Eds., CBS Publishers and Distributors, New Delhi, 2002, pp.236-55.

2.        Chien Y.W., “ Controlled and Modulated Release Drug Delivery Systems”, in Encyclopedia of Pharmaceutical Technology, J. Swarbrick, J.C. Boylan, Eds., Marcel Dekker Inc., New York, 1990, pp. 280-285.

3.        Deshpande AA et al. Development of a novel controlled-release system for gastric retention. Pharm Res. 1997; 14: 815-819.

4.        Davis SS et al. The effect of density on the gastric emptying of single and multiple unit dosage forms. Pharm Res. 1986; 3: 208-213.

5.        Lehr CM. Bioadhesion technologies for the delivery of peptide and protein drugs to the gastrointestinal tract. Crit. Rev. Ther. Drug Carrier Syst. 1994; 11: 119-160.

6.        Groning R, Heun G. Dosage forms with controlled gastrointestinal passage studies on the absorption of nitrofurantion. Int J Pharm. 1989; 56: 111-116.

7.        Rouge N et al. Drug absorption sites in the gastrointestinal tract and dosage forms for site specific delivery. Int J Pharm. 1996; 136: 117-139.

8.        Ikeda K, Murata K, Kobayashi M, Noda K. Enhancement of bioavailability of dopamine via nasal route in beagle dogs. Chem Pharm Bull 1992;40:2155-2158.

9.        Hannah B. Noval bioadhesive formulation in drug delivery .16-19.

10.     Chawla, G. et al., Pharm.Tech., 27(7): 50-51,  2003.

11.     Chickering, D.E. et al., Reactive Polymers, 1995, (25): 189-206.

12.     Seng CH.J Pharm Sci 1995;74(4):399-405.

13.     Singh BN, Kim KH.  J. Controlled Release 2000;63(1-2):235-259.

14.     Cremer K. Pharm. J 1997;19:(108):259.

15.     Whitehead L et al, Development of a gastroretentive dosage form. Eur. J. Pharm. Sci. 1996; 4 (Suppl.): S 182.

16.     Harrigan RM. Drug delivery device for preventing contact of undissolved drug with the stomach lining, US Patent 4, 055, 178, October 25, 1977.

17.     Vyas, S.P. and Khar., “Targeted and Controlled Drug Delivery Novel Carrier System”, Ist Ed., CBS. pp. 417-54.

18.     Shiv Kr, H.G. et al, I.J.P.E., 38(4), Oct-Dec,2004.

19.     Soppimath, K.S. et al., T.M., Drug Dev. Ind. Pharm., 27(6): 507-15, 2001.

20.     Klausner EA et al., Novel Levodopa gastroretentive dosage form: in vivo evaluation in dogs. J. Controlled  release. 2003; 88: 117-126.

 

Received on 30.11.2009

Accepted on 27.01.2010        

© A&V Publication all right reserved

Research Journal of Pharmaceutical Dosage Forms and Technology. 2(1): Jan. –Feb. 2010, 28-31